ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1329

Prevalence of Bone Fragility on DXA and CT in Patients with Obesity

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1441

Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1558

Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1518

Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1349

Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1336

Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1319

Prognostic Utility of Metacarpal Bone Mineral Density Measurement in Patients with Recent-onset Arthritis by Assessment of Radiographic Progression at 2-year Follow Up

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1536

Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1163

Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1537

Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1342

Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1474

Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1552

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1374

Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1387

Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe

RA – Diagnosis, Manifestations, and Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].